UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008328
Receipt number R000009737
Scientific Title Detection of histological type and genetic mutation in lung cancer using ion mobility spectrometry
Date of disclosure of the study information 2012/07/03
Last modified on 2018/07/30 11:12:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Detection of histological type and genetic mutation in lung cancer using ion mobility spectrometry

Acronym

Diagnosis of lung cancer using IMS

Scientific Title

Detection of histological type and genetic mutation in lung cancer using ion mobility spectrometry

Scientific Title:Acronym

Diagnosis of lung cancer using IMS

Region

Japan


Condition

Condition

To investigate if IMS can diagnosis histological type and genetic mutation using volatile organic compounds (VOCs) in patients with lung cancer.

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To identify specific VOC patterns in patients with lung cancer.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To investigate if IMS can diagnosis histological type and genetic mutation using volatile organic compounds (VOCs) in patients with lung cancer.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Device,equipment

Interventions/Control_1

Lung cancer:
To collect 10ml of exhaled air using BioScout.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) No treatment of lung cancer
2) To agree to give informed consent

Key exclusion criteria

1) To refuse to give informed consent
2) Lung cancer of unknown histological type
3) Patients with no diagnosis of lung cancer
4) Patients who are pregnant, possibly pregnant, or lactating.
5) Patients with renal failure. (serum creatinine > 2.0 mg/dL, BUN > 30mg/dl)
6) AST or ALT > 100IU
7) Patients with severe diabetes, hyperlipidemia or hyperuricemia
8) Patients who are judged inappropriate by the doctor in charge.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Teruomi Miyazawa

Organization

St. Marianna University School of Medicine
Division of Respiratory and Infectious Diseases, Department of Internal Medicine

Division name

Division of Respiratory and Infectious Diseases, Department of Internal Medicine

Zip code


Address

2-16-1 Sugao Miyamae-ku, Kawasaki, Kanagawa, Japan 216-8511

TEL

044-977-8111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Hiroshi Handa

Organization

St. Marianna University School of Medicine

Division name

Division of Respiratory and Infectious Diseases, Department of Internal Medicine

Zip code


Address

2-16-1 Sugao Miyamae-ku, Kawasaki, Kanagawa, Japan 216-8511

TEL

044-977-8111

Homepage URL


Email



Sponsor or person

Institute

St. Marianna University School of Medicine
Division of Respiratory and Infectious Diseases, Department of Internal Medicine

Institute

Department

Personal name



Funding Source

Organization

St. Marianna University School of Medicine
Division of Respiratory and Infectious Diseases, Department of Internal Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 07 Month 03 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 06 Month 26 Day

Date of IRB


Anticipated trial start date

2012 Year 07 Month 01 Day

Last follow-up date

2014 Year 05 Month 01 Day

Date of closure to data entry

2014 Year 05 Month 01 Day

Date trial data considered complete

2014 Year 05 Month 01 Day

Date analysis concluded

2014 Year 05 Month 01 Day


Other

Other related information



Management information

Registered date

2012 Year 07 Month 03 Day

Last modified on

2018 Year 07 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009737


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name